Skip to main content
Top
Published in: Clinical Rheumatology 2/2012

01-02-2012 | Original Article

Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life

Authors: Yousra Ibn Yacoub, Bouchra Amine, Assia Laatiris, Najia Hajjaj-Hassouni

Published in: Clinical Rheumatology | Issue 2/2012

Login to get access

Abstract

We aimed to evaluate the immunological status and its relationships with disease-related parameters of activity, severity and quality of life in Moroccan patients with rheumatoid arthritis (RA). Two hundred forty-five consecutive patients with RA were recruited. The following data were collected: demographic characteristics, disease duration (years), disease activity (evaluated by the disease activity score, DAS28), structural damage (evaluated by Sharp's method as modified by van der Heijde), functional disability (assessed by using the Moroccan version of the Health Assessment Questionnaire, HAQ) and quality of life (by using the Arabic version of the Medical Outcomes Study Short Form 36 Health Survey: the SF-36). Immunological status (rheumatoid factor rate, RF) and antibodies against citrullinated peptides rate (ACPAs) by the Elisa method were examined. ACPAs were detected in 75.1% of patients with a mean rate of 79.2 ± 43.8 UI. RF was detected in 80.8% of patients with a mean rate of 80.1 ± 50.6 UI. Patients with positive RF and ACPAs had higher disease activity, impaired functional ability, severe structural damage, more ocular symptoms and altered aspects of quality of life. In univariate analysis, higher levels of ACPAs were significantly correlated with the age at onset (r = 0.307), disease duration (r = 0.520), disease activity (DAS28) (r = 0.531), Sharp score (r = 0.431), and with the deterioration of all domains of SF-36 (for all p ≤ 0.01). RF levels were correlated with disease duration (r = 0.517), disease activity (r = 0.470), functional disability (r = 0.521), and the alteration of physical domains of SF-36 (for all p ≤ 0.01). In multivariate analysis, the main factors associated to ACPAs and RF levels were functional disability, structural damage and impaired QoL. Furthermore, using the SF-36 scores as dependent variables, the impairment of physical domains and the domain of vitality were significantly associated with ACPA levels while the decrease of the domain of physical function was associated with the level of RF. Our study suggests that the presence and the levels of ACPAs and RF in our RA patients are associated with more active disease, more severe joint damage, worst functional disability and altered aspects of quality of life.
Literature
1.
go back to reference Singwe-Ngandeu M, Finckh A, Bas S, Tiercy JM, Gabay C (2010) Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients. Arthritis Res Ther 12(2):R36PubMedCrossRef Singwe-Ngandeu M, Finckh A, Bas S, Tiercy JM, Gabay C (2010) Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients. Arthritis Res Ther 12(2):R36PubMedCrossRef
2.
go back to reference Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, Tomooka BH, Gregersen PK, Robinson WH (2008) Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 10(4):R94PubMedCrossRef Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, Tomooka BH, Gregersen PK, Robinson WH (2008) Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 10(4):R94PubMedCrossRef
3.
go back to reference Kim HH, Kim J, Park SH, Kim SK, Kim OD, Choe JY (2010) Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients. Korean J Intern Med 25(2):201–206PubMedCrossRef Kim HH, Kim J, Park SH, Kim SK, Kim OD, Choe JY (2010) Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients. Korean J Intern Med 25(2):201–206PubMedCrossRef
4.
go back to reference Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65(7):845–851PubMedCrossRef Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65(7):845–851PubMedCrossRef
5.
go back to reference Mimori T (2005) Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med 44(11):1122–1126PubMedCrossRef Mimori T (2005) Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med 44(11):1122–1126PubMedCrossRef
6.
go back to reference Svärd A, Kastbom A, Reckner-Olsson A, Skogh T (2008) Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res Ther 10(4):R75PubMedCrossRef Svärd A, Kastbom A, Reckner-Olsson A, Skogh T (2008) Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res Ther 10(4):R75PubMedCrossRef
7.
go back to reference Pedersen M, Jacobsen S, Garred P, Madsen HO, Klarlund M, Svejgaard A, Pedersen BV, Wohlfahrt J, Frisch M (2007) Strong combined gene–environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case–control study in Denmark. Arthritis Rheum 56:1446–1453PubMedCrossRef Pedersen M, Jacobsen S, Garred P, Madsen HO, Klarlund M, Svejgaard A, Pedersen BV, Wohlfahrt J, Frisch M (2007) Strong combined gene–environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case–control study in Denmark. Arthritis Rheum 56:1446–1453PubMedCrossRef
8.
go back to reference CruyssenVander B, Nogueira L, Van Praet J, Deforce D, Elewaut D, Serre G, De Keyser F (2008) Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis 67:542–546CrossRef CruyssenVander B, Nogueira L, Van Praet J, Deforce D, Elewaut D, Serre G, De Keyser F (2008) Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis 67:542–546CrossRef
9.
go back to reference Egerer K, Feist E, Burmester GR (2009) The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens. Dtsch Arztebl Int 106(10):159–163PubMed Egerer K, Feist E, Burmester GR (2009) The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens. Dtsch Arztebl Int 106(10):159–163PubMed
10.
go back to reference Farouk HM, Mansour HE, Rahman SA, Mostafa AA, Shamy HA, Zarouk WA (2009) Effect of the human leukocyte antigen HLA-DRB1 and anti-cyclic citrullinated peptide on the outcome of rheumatoid arthritis patients. Braz J Med Biol Res 42(9):831–838PubMedCrossRef Farouk HM, Mansour HE, Rahman SA, Mostafa AA, Shamy HA, Zarouk WA (2009) Effect of the human leukocyte antigen HLA-DRB1 and anti-cyclic citrullinated peptide on the outcome of rheumatoid arthritis patients. Braz J Med Biol Res 42(9):831–838PubMedCrossRef
11.
go back to reference Fathi NA, Ezz-Eldin AM, Mosad E, Bakry RM, Hamed HB, Ahmed S, Mahmoud M, Rashed HA, Abdullah F (2008) Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis. Int Arch Med 1(1):20PubMedCrossRef Fathi NA, Ezz-Eldin AM, Mosad E, Bakry RM, Hamed HB, Ahmed S, Mahmoud M, Rashed HA, Abdullah F (2008) Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-citrullinated peptide antibodies and HLA-DRB1 locus genes in rheumatoid arthritis. Int Arch Med 1(1):20PubMedCrossRef
12.
go back to reference Cader MZ, Filer AD, Buckley CD, Raza K (2010) The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis. BMC Musculoskelet Disord 11:187PubMedCrossRef Cader MZ, Filer AD, Buckley CD, Raza K (2010) The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis. BMC Musculoskelet Disord 11:187PubMedCrossRef
13.
go back to reference Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM (2008) Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scand J Rheumatol 37(5):329–336PubMedCrossRef Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM (2008) Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scand J Rheumatol 37(5):329–336PubMedCrossRef
14.
go back to reference Zoler ML (2009) New Rheumatoid Arthritis Criteria Released by ACR/EULAR Panel. Elsevier Global Medical News Zoler ML (2009) New Rheumatoid Arthritis Criteria Released by ACR/EULAR Panel. Elsevier Global Medical News
15.
go back to reference Van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB (1995) Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 22(9):1792–1796PubMed Van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB (1995) Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 22(9):1792–1796PubMed
16.
go back to reference Abourazzak FE, Benbouazza K, Amine B, Bahiri R, Lazrak N, Bzami F, Jroundi I, Abouqal R, Guillemin F, Hajjaj-Hassouni N (2008) Psychometric evaluation of a Moroccan version of health assessment questionnaire for use in Moroccan patients with rheumatoid arthritis. Rheumatol Int 28(12):1197–1203PubMedCrossRef Abourazzak FE, Benbouazza K, Amine B, Bahiri R, Lazrak N, Bzami F, Jroundi I, Abouqal R, Guillemin F, Hajjaj-Hassouni N (2008) Psychometric evaluation of a Moroccan version of health assessment questionnaire for use in Moroccan patients with rheumatoid arthritis. Rheumatol Int 28(12):1197–1203PubMedCrossRef
17.
go back to reference Khoudri I, Ali Zeggwagh A, Abidi K, Madani N, Abouqal R (2007) Measurement properties of the short form 36 and health-related quality of life after intensive care in Morocco. Acta Anaesthesiol Scand 51(2):189–197PubMedCrossRef Khoudri I, Ali Zeggwagh A, Abidi K, Madani N, Abouqal R (2007) Measurement properties of the short form 36 and health-related quality of life after intensive care in Morocco. Acta Anaesthesiol Scand 51(2):189–197PubMedCrossRef
18.
go back to reference Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, Montgomery DS, Binks MH, Wilson AG (2006) Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 8(4):R128PubMedCrossRef Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, Montgomery DS, Binks MH, Wilson AG (2006) Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 8(4):R128PubMedCrossRef
19.
go back to reference Hajjaj-Hassouni N, Hassouni F, Guedira N, Lazrak N (1994) La polyarthrite rhumatoïde au Maroc: à propos de 444 cas. La Semaine des hôpitaux de Paris 70:12–20 Hajjaj-Hassouni N, Hassouni F, Guedira N, Lazrak N (1994) La polyarthrite rhumatoïde au Maroc: à propos de 444 cas. La Semaine des hôpitaux de Paris 70:12–20
20.
go back to reference Itty S, Pulido JS, Bakri SJ, Baratz KH, Matteson EL, Hodge DO (2008) Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis. Trans Am Ophthalmol Soc 106:75–81PubMed Itty S, Pulido JS, Bakri SJ, Baratz KH, Matteson EL, Hodge DO (2008) Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis. Trans Am Ophthalmol Soc 106:75–81PubMed
21.
go back to reference Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430PubMedCrossRef Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430PubMedCrossRef
22.
go back to reference Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63(9):1090–1095PubMedCrossRef Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63(9):1090–1095PubMedCrossRef
23.
go back to reference Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42(5):677–680CrossRef Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42(5):677–680CrossRef
24.
go back to reference Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7(5):R949–R958PubMedCrossRef Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7(5):R949–R958PubMedCrossRef
25.
go back to reference Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63(9):1085–1089PubMedCrossRef Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63(9):1085–1089PubMedCrossRef
26.
go back to reference Serdaroğlu M, Cakirbay H, Değer O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28(10):965–970PubMedCrossRef Serdaroğlu M, Cakirbay H, Değer O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28(10):965–970PubMedCrossRef
27.
go back to reference Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRef Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRef
28.
go back to reference Mocanu C, Barjovanu F, Barascu D (2007) Sicca syndrome in major collagen diseases. Oftalmologia 51:56–63PubMed Mocanu C, Barjovanu F, Barascu D (2007) Sicca syndrome in major collagen diseases. Oftalmologia 51:56–63PubMed
29.
go back to reference Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J (2007) Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66(1):59–64PubMedCrossRef Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J (2007) Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66(1):59–64PubMedCrossRef
30.
go back to reference West E, Wållberg-Jonsson S (2009) Health-related quality of life in Swedish men and women with early rheumatoid arthritis. Gend Med 6(4):544–554PubMedCrossRef West E, Wållberg-Jonsson S (2009) Health-related quality of life in Swedish men and women with early rheumatoid arthritis. Gend Med 6(4):544–554PubMedCrossRef
31.
go back to reference Haroon N, Aggarwal A, Lawrence A, Agarwal V, Misra R (2007) Impact of rheumatoid arthritis on quality of life. Mod Rheumatol 17(4):290–295PubMedCrossRef Haroon N, Aggarwal A, Lawrence A, Agarwal V, Misra R (2007) Impact of rheumatoid arthritis on quality of life. Mod Rheumatol 17(4):290–295PubMedCrossRef
32.
go back to reference Garip Y, Eser F, Bodur H (2010) Health-related quality of life in rheumatoid arthritis: comparison of RAQoL with other scales in terms of disease activity, severity of pain, and functional status. Rheumatol Int 31:769–772PubMedCrossRef Garip Y, Eser F, Bodur H (2010) Health-related quality of life in rheumatoid arthritis: comparison of RAQoL with other scales in terms of disease activity, severity of pain, and functional status. Rheumatol Int 31:769–772PubMedCrossRef
33.
go back to reference Prajs K, Flicinski J, Brzosko I, Przepiera-Bedzak H, Ostane kL, Brzosko M (2006) Quality of life and activity of disease in patients with rheumatoid arthritis. Ann Acad Med Stetin 52:39–43PubMed Prajs K, Flicinski J, Brzosko I, Przepiera-Bedzak H, Ostane kL, Brzosko M (2006) Quality of life and activity of disease in patients with rheumatoid arthritis. Ann Acad Med Stetin 52:39–43PubMed
34.
go back to reference Ibn Yacoub Y, Amine B, Laatiris A, Wafki F, Znat F, Hajjaj-Hassouni N (2011) Fatigue and severity of rheumatoid arthritis in Moroccan patients. Rheumatol Int. (in press) Ibn Yacoub Y, Amine B, Laatiris A, Wafki F, Znat F, Hajjaj-Hassouni N (2011) Fatigue and severity of rheumatoid arthritis in Moroccan patients. Rheumatol Int. (in press)
Metadata
Title
Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life
Authors
Yousra Ibn Yacoub
Bouchra Amine
Assia Laatiris
Najia Hajjaj-Hassouni
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1820-4

Other articles of this Issue 2/2012

Clinical Rheumatology 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine